Good morning, HealthTech insiders. For years, venture capital funded point-solution software tools that promised to make clinicians faster, only to leave medical groups wrestling with disconnected dashboards, alert fatigue, and uncompensated integration costs. Today, the operational model of clinical AI is showing signs of a pivot from software overlays to vertically integrated clinical infrastructure. Epsilon Health emerged from stealth with $27.6 million led by AlleyCorp to scale a technology-native radiology medical group, while Implicity secured $40 million to scale its cross-manufacturer remote cardiac monitoring network across more than 250 medical centers.
At the same time, clinical validation is expanding from isolated retrospective algorithmic benchmarks to real-world multimodal studies and physician usability assessments. In Nature Medicine, the international I3LUNG consortium evaluated explainable AI across 2,396 advanced non-small cell lung cancer patients, demonstrating its potential to support immunotherapy outcome predictions. Whether in tele-diagnostics, electrophysiology, or precision oncology, the emerging thesis is clear: software alone does not transform healthcare without direct clinical and operational accountability.
In today's Signal:
Epsilon Health Launches AI-Native Radiology Group: AlleyCorp leads $27.6M in funding to combine machine learning workflow infrastructure with a professional clinical practice.
Nature Medicine Publishes I3LUNG Validation: A 2,396-patient international study shows explainable AI can improve physicians’ outcome predictions for advanced lung cancer immunotherapy.
Implicity Secures $40M Growth Equity: IRIS, alongside Five Arrows, funds expansion of universal cardiac remote monitoring with FDA-cleared algorithms across more than 120,000 patients monitored daily.
The Investor's Signal: Why capital is backing full-stack tech-enabled provider groups and automated back-office revenue engines.
In partnership with
Find Out What's Holding Your Revenue Back
Your business didn't plateau overnight. Growth slowed one bottleneck at a time.
But more hours at the office, more hires, and more marketing won't remove a hidden limitation. They just make it harder to spot.
The Revenue Ceiling Report reveals the four most common growth ceilings so you can identify what's quietly costing your business revenue and what to do next.
BELAY’s U.S.-based Assistants help build the systems and support that turn sustainable growth into reality.
LATEST DEVELOPMENTS
AI & RADIOLOGY
1. Epsilon Health Emerges From Stealth With $27.6M to Build AI-Native Radiology Practice
Source: Business Wire
Epsilon Health has officially launched out of stealth mode with $27.6 million in venture capital, led by AlleyCorp with participation from Uncork Capital, Renegade Partners, SemperVirens, and Jack Altman, establishing an AI-native radiology practice designed to tackle nationwide radiologist shortages through vertically integrated clinical operations.
The details:
Full-Stack Medical Group Architecture: Rather than selling software licenses to overloaded hospital imaging departments, Epsilon operates as a clinical radiology practice with board-certified radiologists supported by proprietary AI workflow infrastructure.
Addressing Severe Workforce Deficits: With imaging demand rising while the US faces a radiologist shortage, Epsilon's operating model targets turnaround time compression and burnout reduction. The company cites an estimate that 75% of medical decisions rely on radiology.
Experienced Clinical Leadership: Founded by CEO Rustin Rassoli, with veteran radiology operator Roi Bittane serving as Chief Medical Officer, Epsilon combines AI expertise with experience leading major US radiology practices. Epsilon announcement, Uncork investment announcement
The Signal: Epsilon represents the maturation of healthcare AI from tool-vendor to full-stack clinical provider. Its model offers health systems an alternative to complex multi-vendor software integration projects: contracting directly with technology-augmented physician groups that manage the technology within their own clinical operations.
RESEARCH & PRECISION ONCOLOGY
2. Nature Medicine Publishes I3LUNG Study: AI Evaluated in 2,396 Advanced Lung Cancer Patients
Overview of the I3LUNG study and patient dataset. Source: Prelaj et al., Nature Medicine (2026).
In a paper published in Nature Medicine, Dr. Arsela Prelaj and the international I3LUNG consortium demonstrated that explainable AI can support treatment outcome predictions for patients with advanced non-small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor therapy.
The details:
Large Multimodal Cohort: The study evaluated clinical and blood data, with radiological, genomic, and pathological data available in subsets, across 2,396 stage IIIC–IVB NSCLC patients from six international cancer centers. Complete data across all studied modalities were available for 339 patients.
Explainable AI Bridges Clinician Gap: Utilizing SHAP-based explainability frameworks, a clinical-and-blood-data model improved outcome predictions in a retrospective exercise involving 20 medical oncologists reviewing 100 cases, including both lung cancer experts and nonexperts.
Active Prospective Validation Underway: Building on these findings, the I3LUNG consortium describes ongoing silent prospective validation in 2,000 patients and a planned pragmatic randomized trial to support regulatory approval.
The Signal: Single-biomarker approaches like PD-L1 immunohistochemistry have predictive limitations in oncology. Routine clinical and blood data showed robust predictive value in this study. Although adding imaging improved some results, those gains were inconsistent in held-out testing, and multimodal integration’s added value needs further validation. Published study
FUNDING & CARDIAC MONITORING
3. Implicity Secures $40M Growth Equity From IRIS and Five Arrows to Expand Universal Cardiac AI
Implicity raises $40 million to expand its AI-driven cardiac remote monitoring platform. Source: IRIS.
Implicity, the digital MedTech company founded by cardiac electrophysiologist Dr. Arnaud Rosier, has secured $40 million in growth equity funding led by European tech growth firm IRIS, alongside Five Arrows (the alternative assets arm of Rothschild & Co), accelerating the US expansion of its universal remote cardiac monitoring platform.
The details:
Universal Device Interoperability: Implicity aggregates and normalizes telemetry data from all major cardiac implant manufacturers (Medtronic, Abbott, Boston Scientific, Biotronik, and MicroPort), consolidating the fragmented vendor-specific data streams that currently overwhelm hospital electrophysiology clinics.
FDA-Cleared Clinical Intelligence: Powered by FDA-cleared algorithms including SignalHF (heart failure risk prediction) and its ILR ECG Analyzer, the platform supports clinical monitoring and alert filtering. The ECG Analyzer reduced false-positive episodes by up to 76% in published research; separately, an observational study of ICD patients associated universal monitoring with 26% lower mortality than conventional remote monitoring. Analyzer announcement, Mortality study
Scale Across 250+ Medical Centers: The platform currently monitors over 120,000 patients daily across the US, France, and Germany, providing automated documentation and billing workflow support for remote cardiac monitoring. Funding announcement
The Signal: Remote cardiac monitoring cannot scale efficiently if clinical teams must manually triage millions of raw telemetry transmissions across five proprietary manufacturer silos. Implicity illustrates how universal data normalization paired with FDA-cleared noise reduction can reduce administrative burden and support clinical care.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
1. Tech-Enabled Provider Group Economics: We're watching whether Epsilon Health's AI-native medical group model can maintain superior diagnostic turnaround times while navigating state corporate practice of medicine (CPOM) regulations and national health system teleradiology contracts.
2. I3LUNG Prospective Validation: We're watching performance in the ongoing 2,000-patient silent prospective validation and progress toward a randomized trial to assess clinical impact and support regulatory approval.
3. Payer Remote Monitoring Audits: We're watching commercial health plan and Medicare MAC enforcement around documentation and billing requirements for implantable cardiac device monitoring, which uses a separate coding framework from general remote physiologic monitoring.
💰 FOLLOW THE MONEY
The deals:
GenHealth.ai ($16.5M Series A): Flare Capital Partners led the financing with Craft Ventures, Obvious Ventures, and Eniac Ventures to scale autonomous AI agents that run medical back-office workflows across EHRs and payer portals.
Thyme Care ($125M+ Series E & Thyme Companies): Morgan Health led the round at a $2B+ valuation with Humana and CVS Health Ventures to expand value-based oncology navigation and establish a parent organization for new oncology businesses.
Verily Health (Strategic Expansion from NVIDIA): Verily secured growth capital from NVIDIA and the CU Healthcare Innovation Fund to advance precision health foundation models and clinical AI infrastructure.
The pattern: These announcements suggest healthcare growth capital is backing workflow infrastructure that eliminates clinician labor bottlenecks, unifies fragmented multi-vendor hardware, and automates administrative revenue cycles.
📆 UPCOMING HEALTHTECH EVENTS
World Medical Innovation Forum 2026 (Sep 22–23, 2026 · Boston, MA): Mass General Brigham gathering on healthcare AI, oncology translation, and regulatory pathways.
ASTRO 68th Annual Meeting 2026 (Sep 26–30, 2026 · Boston, MA): Premier global radiation oncology conference covering multimodal precision targeting and clinical practice.
HLTH USA 2026 (Nov 15–18, 2026 · Las Vegas, NV): Flagship digital health ecosystem summit exploring enterprise provider consolidation, value-based contracts, and generative AI care delivery.
🛠️ Trending HealthTech AI Tools
AyniHealth: Continuous credentialing and operational compliance platform purpose-built for radiation oncology departments and multi-hospital cancer networks.
SignalHF by Implicity: FDA-cleared Class II predictive machine learning algorithm that analyzes compatible implantable cardiac device data to assess heart failure risk over the next 30 days and support clinical evaluation.
Cortechs.ai NeuroQuant PET: FDA-cleared automated quantification software for amyloid PET imaging, streamlining objective neurological analysis for Alzheimer's disease.
🛠️ Trending HealthTech AI Startups
Throne Science: Austin-based developer of an AI-powered smart bathroom sensor tracking non-invasive stool characteristics, hydration signals, and urinary metrics.
Flagler Health: AI-native operating system designed to automate administrative workflows and patient care pathways for musculoskeletal and orthopedic practices.
Doctronic: AI health conversation and preliminary symptom assessment platform offering access to video visits with licensed physicians.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
Which operating model will dominate healthcare AI adoption over the next 3 years?
That's it for today!
Today's developments across radiology, precision oncology, and electrophysiology highlight a structural evolution in digital health. Much investment has operated under the premise that providing clinicians with algorithms would yield better care and greater efficiency. But algorithms alone do not solve staffing shortages, fragmented device ecosystems, or complex clinical decision-making when disconnected from core operational workflows.
Whether it is Epsilon Health combining radiologists with integrated AI, Implicity normalizing multi-vendor telemetry transmissions, or the I3LUNG consortium evaluating explainable decision support in oncology, clinical adoption requires structural integration. As health systems face relentless financial and labor pressures, the fundamental question for founders and investors extends beyond whether an algorithm works in a benchmark dataset to whether it can deliver measurable value inside clinical practice.
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal